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Murine models have been adopted as a significant and powerful tool in the study of 
cancer. The applications of murine models of cancer are numerous: mechanism discov-
ery, oncogenesis, molecular genetics, microenvironment, metastasis, and therapeutic 
efficacy. Leukemias and lymphomas are a group of highly heterogeneous hematologic 
malignancies that affect people of all ages and ethnicities. Leukemia and lymphoma 
arise from hematopoietic and immune cells and usually spread widely throughout the 
body. The liquid nature of many of these malignancies, as well as the complex micro-
environment from which they arise and their multifaceted genetic basis, has added to 
the difficulty in generating appropriate and translational models to study them. Murine 
models of leukemia and lymphoma have made substantial contributions to our under-
standing of the pathobiology of these disorders in humans. However, while there are 
many advantages to these models, limitations remain. In this review, we discuss the 
mouse as a model to study leukemia and lymphoma, and the importance of choosing 
the correct methodology. Specific examples of murine models of leukemias and lympho-
mas are provided, with particular attention to those that are highly translational to their 
human counterpart. Finally, future applications of murine models and potential for better 
models are discussed.
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iNTRODUCTiON
In “The Principles of Humane Experimental Technique” published in 1959, William Russell and Rex 
Burch proposed that every effort should be made to replace experimental animals with non-sentient 
alternatives, to reduce the number of animals used, and to refine laboratory procedures with the 
aim of causing minimal pain and distress to research animals (1, 2). Now known as the “3Rs,” these 
principles have been since adapted and developed for modern biomedical research uses.
A key goal of biomedical research is to provide clinicians with advanced knowledge to predict 
disease pathology and select appropriate treatment. While much of the work done in research is 
accomplished in  vitro or in  silico, the predictive value of these data is ultimately limited by the 
complexity of whole-organism systems. The critical advantage of animal models is that it can be 
used to test relationships and mechanisms under controlled experimental conditions, which can 
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then be translated to predict human clinical outcomes. The chal-
lenge falls to researchers to anticipate distinct differences between 
cellular behavior in vitro in contrast to in vivo, and additionally 
the inherent differences between species to generate data that is 
translatable to the clinic.
Mouse models of human disease are highly valuable in 
biomedical research, but only with appropriate validation and 
careful consideration of the compatibility of the data with human 
disease (3). Validation involves determining the extent to which 
the mouse phenotype mimics the clinical characteristics of the 
human illness (3). For the study of cancer, in particular, the 
ideal murine model should replicate the genetic and molecular 
heterogeneity of tumors and involve de novo tumors in immune-
competent mice while also mimicking clinical behavior of the 
human disease. These murine models should develop tumors 
with high penetrance and reproducibility, while also offering a 
mechanism of monitoring disease progression and treatment 
efficacy (4).
THe MOUSe AS A MODeL
Many organisms are available to research scientists, each with 
their advantages and disadvantages for the study of individual 
organ systems and disease types. Despite the wide variety of avail-
able model systems, the mouse (Mus musculus) is now widely 
considered the model organism of choice for the study of human 
disease. The reasons for this choice are numerous, including the 
relative genetic similarity of mice to humans, their small size, 
reliable breeding, and short life span. Mice also share many physi-
ologic characteristics with humans and, therefore, provide similar 
organ system biology for the study of cardiovascular, endocrine, 
immune diseases, and others.
Historically, mice were used in genetic experiments as early as 
1930 due to their abundant availability (5). Today, breeding inbred 
strains, developing models, and shipping mice for research use is 
a major industry. There are strains that spontaneously develop 
diseases of interest, as well as genetically manipulated strains that 
are prone to developing certain cancers, obesity, glaucoma, etc. 
(5). Additional models available include immunodeficient mice 
that are valuable for the study of cancer and certain infectious 
diseases, as well as being acceptable hosts for human tissue and 
cells. Powerful tools available to compare mouse and human 
genomes have allowed comprehensive genomic manipulation 
in the mouse to mimic human disease pathophysiology (5). For 
conditions lacking an accurate model, experimental approaches 
to humanize mice can be used to more closely mimic human 
disease.
For all of their advantages, there are also numerous limita-
tions that must be considered when choosing the model and 
interpreting their findings. From the conception of the 
model, through development, data collection, and interpreta-
tion, the idiosyncrasies superimposed onto the data by the 
“mouse factor” must be considered. One prominent example 
of this problem is in the general unfamiliarity of background 
lesions in different mouse strains. Some spontaneous disease 
conditions are strain or age related; and while inbred mice are 
genetically extremely similar, minor differences exist and can 
result in variability within the study. Therefore, while the mouse 
is a powerful tool, it must also be viewed as an independent 
contributor to the research conducted upon it and as one that 
deserves consideration.
Concerning hematopoiesis, in mice, lymphocytes are the 
predominant circulating white blood cell, whereas the neutrophil 
predominates in humans (3, 6, 7). Importantly, extramedullary 
hematopoiesis in the red pulp of the spleen is physiologic in the 
adult mouse and can be exuberant and should not interpreted as 
neoplasia (6). Additionally, bone marrow in the mouse retains 
abundant hematopoietic components throughout life in contrast 
to the paucicellular marrow of adult humans. Also, ectopic thymic 
tissue in the mouse can be found commonly in various locations 
in the cervical region, and should not be confused with infiltrative 
neoplasia (3).
CHOOSiNG THe CORReCT MODeL
The choice of model is often the first and most important consid-
eration in developing in vivo research studies. First and foremost, 
is the mouse the best model? It may not be. It may be that better 
models are available but too expensive or otherwise not practical. 
For modeling many diseases, particularly cancer, there is likely no 
significant difference between the utility of the mouse versus other 
laboratory species, and the decision comes down to availability 
and cost. Murine models are abundantly plentiful commercially, 
and as a standard of research are often easiest to cite and utilize 
previous work to develop your model.
One early and critical consideration is the selection of the 
strain of mouse. Inbred strains are the result of greater than 20 
consecutive generations of sister–brother or parent–offspring 
matings. These mice will be homozygous at virtually all loci. 
Each strain has distinguishing characteristics as well as signifi-
cant genotypic and phenotypic differences within a single strain. 
Often, it is acceptable and sufficient to access online databases 
to choose your knockout of interest, on a standard background 
strain, such as FVB/N, BALB/c, or C57BL/6. C57BL/6 are 
often utilized for mutagenesis studies and are overall the most 
commonly used strain in academic institutions (3). Frequent 
spontaneous diseases in C57BL/6 include hydrocephalus, 
staphylococcal dermatitis, and pulmonary proteinosis (7). 
BALB/c mice commonly develop myocardial degeneration and 
left auricular thrombosis. FVB/N mice are often used to generate 
transgenic animals as they have large pronuclei for gene injection 
and tend to be natural superovulators. This strain is prone to 
development of seizures and mammary hyperplasia secondary 
to prolactinomas (7). One hundred twenty-nine mice are often 
used as donors of embryonic stem cells and are prone to pulmo-
nary proteinosis and hypocollosity (7). Aside from these com-
mon background findings, each of these strains is predisposed 
to developing certain spontaneous tumors, with lymphoma 
often being most common (7). The high incidence of leukemia 
and lymphoma in some mouse strains is further enhanced in 
immunocompromised mice—an experimental tool often used 
to model these diseases. Some spontaneous leukemias, in par-
ticular, can be difficult to distinguish from the disease model 
manipulation. It is clear that many of these conditions could 
TABLe 1 | Advantages and disadvantages of types of murine models.
Model Advantages Disadvantages
Spontaneous No/minimal manipulation needed
Whole-organism system available to study disease pathogenesis
May not be accurate/translational to human disease 
condition
Typically arises in older animals—time consuming 
and more costly
Xenograft (cell line-derived) Relative simplicity Lack of organ/system microenvironment (except for 
orthotopic)High yield
Rapid results Lack of immune system interaction with tumor cells
Relative inability to test complex genomic 
interactions in a single-cell system
Cell lines likely differ significantly from parental 
source (tumor)
Relatively inexpensive
Multiple routes of administration
Avoid immune rejection with immunocompromised strains (commercially 
available)
Useful as first step investigation
Useful as confirmatory for in vitro findings
Xenograft (patient-derived) Relative simplicity Lack of organ/system microenvironment (except for 
orthotopic)High yield
Rapid results Lack of immune system interaction with tumor cells
Relative inability to test complex genomic 
interactions in a single-cell system
Multiple routes of administration
Avoid immune rejection with immunocompromised strains (commercially 
available)
Useful as first step investigation
More true representation of tumor cell biology than above
Useful for investigation into efficacy of therapeutics on human tumor cells
Humanized mice Competent immune system to model tumor–immune interaction Expensive
Can engraft cell lines, human tumor tissue, or genetically manipulated cells Time consuming
More true representation of tumor cell biology in a human-like system Generally need to establish breeding colony
Useful for investigation of tumor pathobiology
Germline transgenic Faithful alteration of gene of interest Transgene is universally expressed in every tissue
Immunocompetent mice
Useful for testing tumor development
Useful for testing therapeutic approaches
Useful for testing chemopreventative techniques
Transgene is expressed throughout embryologic 
development
Genetically not as complex as many human tumors




Useful for testing tumor development
Useful for testing therapeutic approaches
Useful for testing chemopreventative techniques
Many mice will not carry desired genotype following 
crossing
Genetically not as complex as many human tumors
Multi-allelic transgenics (clustered 
regularly interspaced short 
palindromic repeats-Cas9)
Multiple genes can be manipulated to more closely mimic disease complexity Challenging technique
Ability to test cooperating mutations Expensive
Potential of off-target mutations
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confound individual studies, and therefore, the strain of mouse 
must be considered carefully.
DeveLOPeD MOUSe MODeLS AND 
THeiR UTiLiTY
There are multiple advantages of using the mouse with regard 
to its genetic similarity to people, including a similar number 
of protein-coding genes, 40% direct gene alignment between 
the two species, and the finding that 99% of human genes have 
homologous genes in the mouse (6, 8). Advances in genomic 
techniques have allowed development of highly translational 
murine models of hematologic malignancies. Classifications 
of murine models of human hematologic neoplasia include 
spontaneous, xenograft, and genetically engineered models 
(Table 1).
Xenograft models are relatively simple, high-yield, potentially 
high-reward systems, which can be used to begin investigations 
into tumor biology. Human tumor tissue or tumor-derived cell 
lines are transplanted subcutaneously, intravenously, or ortho-
topically into the organ type of origin (Figure 1). These models 
are conducted in immunocompromised mice to avoid immune 
rejection of the human cells (9). Immunocompromised mice 
range from athymic nude to variations on severe combined immu-
nodeficiency (SCID) mice. Nude mice are generated on BALB/c 
background utilizing a mutation in Foxn1 resulting in the lack 
of thymic development, and therefore thymus-derived mature 
T cells. Importantly, these mice still carry B cells, granulocytes, 
FiGURe 1 | Xenograft model. Cell line-derived (A) or patient-derived 
(B) cells can be transplanted into immunocompromised mice to study several 
aspects of tumor biology and behavior.
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dendritic cells, and highly active NK cells. SCID mice are typically 
ΔPrkdc and Rag1 null, derived on a C57BL/6, C3H, or non-obese 
diabetic/LtSzJ backgrounds. These mutations result in the lack of 
functioning B and T cells with minimal to no NK activity. Certain 
commercially available NOD/SCID strains are also somewhat 
resistant to the development of spontaneous lymphoma (10). 
Xenograft models are highly useful in determining in  vivo 
proof-of-concept from in vitro studies as well as examining the 
efficacy of therapeutics on human tumor cells. Their significant 
disadvantages, however, include a general lack of tumor context 
or microenvironment (partially improved by orthotopic models), 
and inability to determine the effects of immune systems on 
tumor growth. NSG™ mice are further immunocompromised 
with an IL2Rγ knockout, rendering these mice deficient in all 
lymphocytes, including NK cells, making these mice more recep-
tive to engraftment. NOD/SCID mice can be “humanized” by the 
addition of human peripheral blood lymphocytes, bone marrow, 
or fetal liver and thymus into irradiated or immunodeficient mice 
(11). This manipulation allows for nearly complete reconstitution 
of immune responses to engrafted tumors.
Limitation of cancer cell lines, include adaptation to in vitro 
culture for extended periods of time and the selective pressure 
therein, which is not reverted during xenografting (12, 13), and 
the relatively minimal genetic diversity available in cell lines as 
compared to the tumors from which they derive (14, 15). To 
overcome some of these limitations, patient-derived xenografts 
(PDXs) are becoming more widely used (15). PDXs can be col-
lected from patients early or late in their disease, as pre-treatment, 
responsive, or refractory to treatment (15). Recently, large thera-
peutic studies in solid tumor PDXs recapitulated response rates 
observed in clinical trials, highlighting the benefits of this model 
in translating data from the lab to the clinic (16).
The genetically engineered mouse model (GEMM) has been 
used to mimic many human cancers with an etiology based in 
genetic aberration. To produce transgenic mice, a gene of inter-
est in the form of a vector is injected into a fertilized egg. The 
resultant offspring will carry additional copies of this transgene 
(Figure 2). The gene of interest may also be engineered to express 
in a tissue-specific pattern or in response to drug treatment (5). 
Importantly, these tumors can be generated using immunocom-
petent mice, allowing investigation of both microenvironment 
and immunity on tumor development and growth. Therapeutic 
intervention can also be tailored to mimic clinical approaches, 
as either preventative or long-term therapy with the ability to 
follow-up tumor response in vivo.
Knockout models introduce loss of function mutations that 
disrupt gene function during embryogenesis, and knock-in 
models add an altered gene (5). One challenge with embryonic 
stem cell manipulation is the presence of genetic alteration during 
development, which may affect aberrant targets and inappropri-
ately model an adult human disease. To avoid this undesirable 
effect, conditional models have been developed by crossing mice 
carrying recombinase effector genes with mice carrying the 
target gene, thus generating a spatially and temporally controlled 
mutation (5). There are available embryonic stem cell lines that 
carry floxed alleles of genes carrying Cre recombinase sites to 
allow transformation into blastocysts; wherein the mutation will 
be activated by crossing the mouse with the desired Cre recom-
binase driver (Figure 2) (5). Germline GEMMs allow research 
into mechanisms of oncogenic transformation, as well as the 
advantage of evaluating the efficacy of therapeutics on tumors 
with an intact microenvironment (4, 17). Inducible germline 
models, or knock-in systems, can be designed to activate muta-
tions in specific tissues in response to drug or vector treatment 
(4, 18). While GEMMs are useful for evaluating the effects of a 
specific genetic alteration in tumor development, they are still not 
able to adequately reproduce the genetic complexity of human 
tumors (9).
Generation of murine models using clustered regularly inter-
spaced short palindromic repeats (CRISPR)-Cas9 genome editing 
is an emerging and powerful tool to study cancer. CRISPR-Cas9 
can be delivered directly into the mouse zygote, generating an 
animal carrying highly targeted genetic modification (19). This 
system creates double stranded DNA breaks in precise locations, 
which are then repaired by somewhat predictable mechanisms, 
and can produce null, conditional, single mutant, reporter, or 
tagged alleles in the mouse (20). Additionally, this system can be 
used to deliver combinations of guide RNAs to modify multiple 
genes in a single mouse hematopoietic stem cell, to more closely 
model the complexity of hematopoietic malignancy (21). Despite 
the risk of off-target editing noted in cell-based systems, recent 
data suggests that CRISPR-mediated editing events are accurate 
in the embryonic system (20, 22). It is likely that RNA-guided 
FiGURe 2 | Transgenic models. (A) Injection of the vector construct into a fertilized egg will generate transgenic offspring that expresses the gene of interest in 
every cell. (B) Conditional transgenics can be generated for tissue-specific expression under the control of a Cre recombinase. These can be crossed with mice 
carrying the floxed gene of interest with resulting offspring carrying the tissue-specific knockout.
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genome editing in  vivo will become the preferred method of 
generating new and improved murine models.
A critical process in developing any murine model is phe-
notypic characterization. Phenotyping a mouse by a qualified 
comparative pathologist involves integration of the strain, 
background lesions, genetic manipulations by the researcher, 
the breeding regimen, the sex, diet, age, and any pathogenic or 
commensal organisms that may exist in the colony. Phenotyping 
often involves a combination of antemortem clinical assessments, 
postmortem pathological evaluation, and additional testing. 
Crossing various genotypes to develop a new paradigm warrants 
subsequent phenotypic characterization of the new line (6).
MURiNe MODeLS OF LeUKeMiA
Due to the many types of leukemia, this review will focus on 
the four major types of leukemia, accounting for 85% of all 
leukemias: acute and chronic myeloid leukemia (AML, CML), 
acute lymphoblastic leukemia (ALL), and chronic lymphocytic 
leukemia (CLL) (18). Incidence as well as survival rates have 
been steadily increasing, the latter due in large part to advancing 
targeted therapeutics (23). Murine models of leukemia have been 
critical in the understanding of leukemogenesis and the develop-
ment of novel targeted therapy.
Of the spontaneous leukemic diseases, AML is the most inten-
sively studied as it accounts for the majority of leukemia-related 
deaths (18, 23). Many of the genetic aberrations involved in the 
oncogenesis of AML have been characterized, with recurrent 
genetic abnormalities to include CEBPA mutations, RUNX1 
mutations, and BCR-ABL1 gene translocations (24) (Table  2). 
Inherited mutations in numerous genes have also been identified 
in myeloid leukemia (24). Murine models have been instrumental 
in elucidating immune interaction, hematopoietic stem cell niche 
and microenvironment, cancer stem cells, novel therapeutics, and 
chemotherapeutic resistance in AML.
Homozygous deletion of the upstream regulatory element 
of PU.1 results in downregulation of this protein within hemat-
opoietic stem and progenitor cells and leukemia development 
in a mouse model of AML (25). Deletion of Tp53 in these mice 
results in a more aggressive disease with shortened survival. 
This model was useful in identifying Myb and miR-155 as con-
tributing to PU.1 downregulation (25). An attractive model of 
myelodysplastic syndrome transformation to AML is a transgenic 
model featuring N-Ras/Bcl-2 mitochondrial complex inducing 
disease progression (26). This model has been used to study the 
therapeutic efficacy of Bcl-2 inhibitors for the treatment of AML 
and other leukemic diseases (26).
Genetic deletion of the telomerase subunit Terc in a retroviral-
induced AML mouse model results in cell-cycle arrest and 
apoptosis of leukemia stem cells (LSCs) which maintain AML 
(27). The LSCs of these TERC (−/−) mice express a similar gene 
expression profile as human AML patients with better survival 
following chemotherapy (27). Inhibition of telomerase in a 
xenograft model shows specific targeting of LSCs with reduced 
disease progression and delayed relapse, identifying telomerase 
as an attractive therapeutic target (27).
CML is characterized by the malignant transformation of 
hematopoietic stem cells, predominantly as a result of dysregu-
lated signaling through tyrosine kinases (28). CML eventually 
progresses to a fatal myeloblastic phase with an accumulation 
TABLe 2 | Murine models of leukemia.
Disease Gene targets Model Translation Therapeutic use
AML PU.1 + p53 Conditional knockout in hematopoietic cells Aggressive AML
Nras:Bcl-2 Conditional transgenic Myelodysplastic syndrome Bcl-2 inhibitors
TERC Conditional knockout Leukemia stem cell maintenance
AML-ETO Inducible transgenic APL
RARα fusion Transgenic, variable AML Transretinoic acid
CML BCR-ABL1 Humanized mice transplanted with retroviral vector Chronic myeloproliferative 
syndrome
Conditional transgenic in hematopoietic cells CML Tyrosine kinase inhibitors




ETV6–RUNX1 Transgenic using Ig heavy chain enhancer Block in B-cell differentiation
E2A–PBX1 Conditional transgenic using Lck enhancer, TCR Vβ promoter B-cell ALL
NOTCH1 Tumor-derived engraftment of NOD/SCID Xenograft T-ALL Monoclonal antibody 
against Notch1





miR-16 Spontaneous in New Zealand Black Clonal CD5+ B cell disease
T-cell leukemia 1 Serial transfer transgenic Rapid progression CLL PD-1 immune checkpoint 
inhibitor
BCR NSG™ with orthotopic splenic engraftment CLL Ibrutinib efficacy
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of immature hematopoietic cells following inactivation of tumor 
suppressors and differentiation factors (29). A reciprocal trans-
location between chromosomes 9 and 22 (t(9;22)–(q34;q11)), 
resulting in fusion protein BCR–ABL1 is a major contributing 
event to CML and has been a dominant therapeutic target (30, 
31) (Table 3). The original description of the murine model by 
Daley et  al. revealed induction of a chronic myeloproliferative 
syndrome in irradiated mice transplanted with a retroviral vector 
encoding the BCR–ABL1 fusion protein that closely resembled 
human CML (30). Other approaches have included xenografts 
with patient cells or cell lines, retroviral transduction of bone 
marrow-derived cells followed by transplantation into irradi-
ated congenic mice, and transgenic mice expressing oncogenic 
BCR–ABL1 (28).
Murine models utilizing retroviral vectors allowed identifica-
tion of regions within the BCR–ABL1 fusion protein that are 
critical for transformation, allowing for the rational design and 
development of tyrosine kinase inhibitors (30). Murine models 
have been used to recapitulate the different clinical phenotypes 
noted in patients with various BCR–ABL1 fusion proteins (38). 
Retroviral murine models also allow functional evaluation of 
individual genes concerning CML development and progression, 
including the finding that STAT5 expression is necessary for 
BCR–ABL1-mediated leukemogenesis (39, 40). In humanized 
models, retroviral expression in cord blood followed by trans-
plantation to immune-deficient mice resulted in an accumulation 
of pre-B-cells, a differentiation block that has been seen in patient 
cells (41).
Non-conditional models have been successful at mimicking 
the clinical characteristics of human patients (42). Particularly, 
use of separate strains of mice to generate inducible models 
allows avoidance of early gene expression (43, 44). Newer trans-
genic models allow expression of the fusion protein exclusively 
within the hematopoietic stem cell compartment (45). While the 
chronic phase of CML is dependent on BCR–ABL1, progression 
to acute blast crisis is mediated by additional genetic alterations, 
and murine models of this disease progression are necessary to 
develop therapies for this patient subset who are unresponsive 
the tyrosine kinase inhibitors (46). A murine model using trans-
poson-based insertional mutagenesis in a background of chronic 
CML elucidated a unique pattern of insertions thus identifying 
candidate genes for the pathogenesis of blast crisis (46). Thus, 
murine models were not only instrumental in the identification 
of the mechanisms of leukemogenesis but also have contributed 
to advances in understanding disease progression in CML and 
identification of novel therapeutic targets.
Acute lymphoblastic leukemia is a disease of childhood 
and older adults, in which many genetic alterations have been 
identified as potential drivers of leukemogenesis. There are T-cell 
and B-cell variants of ALL, each having differing pathogeneses. 
Systems used to study ALL have included syngeneic models and 
xenografts, which have inherent limitations in that they cannot 
model the entirety of host and microenvironment contributions 
to leukemia development (47). Syngeneic models utilize geneti-
cally modified primary cells followed by transplantation, as well 
as the development of transgenic models that alter gene expres-
sion in lymphoid cells (47).
Chromosomal translocation resulting in fusion protein 
ETV6–RUNX1 is the most frequent rearrangement in pediatric 
ALL (48), and its expression correlates with a good prognosis 
(49). Retroviral transduction of this fusion protein does not result 
in leukemia in several models but instead leads to a block in B-cell 
TABLe 3 | Developed murine models featuring expression of oncogenic fusion proteins.
Disease Fusion protein Model Reference
AML BCR–ABL1 NSG xenograft with MSC scaffold (32)
Mixed-lineage leukemia–AF9 NSG xenograft with MSC scaffold (32)
AML1–ETO Irradiated C57BL/6J with intravenous autologous transfected BM cells (33)
CML BCR–ABL1 BCR-ABL retrovirus co-expressing GFP in a triple gene system (34)
ALL ETV6–RUNX1 Inter-cross ETV6–RUNX1 and Pax5 heterogeneic mice (35)
E2A–PBX1 Conditional transgenic E2A–PBX1 under the control of Mb1 or Mx1 promoter-Cre (36)
Peripheral T-cell lymphoma ITK–SYK ITK-SYK cloned into ROSA26 targeting vector, crossed to CD4-Cre (37)
NSG, NOD/SCID IL2Rγ−/− mouse; MSC, mesenchymal stem cell; BM, bone marrow.
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differentiation (50). Neither did leukemia develop in a transgenic 
model utilizing the immunoglobulin heavy chain enhancer to 
drive ETV6–RUNX1 expression (51). Another fusion protein 
in ALL, E2A–PBX1, was expressed under lymphoid-specific Lck 
enhancer and the TCR Vβ promoter to successfully cause B-cell 
ALL when crossed with CD3ε−/− mice (52). The most frequent 
rearrangements occur with mixed-lineage leukemia, conferring 
a worse prognosis (53). Murine models to study many of these 
fusion proteins have had mixed results with regards to the devel-
opment of ALL mimicking the human disease (47).
NOTCH1 activity is increased in a significant population of 
patients with T-ALL secondary to Notch1 mutations or alterations 
in FBW7 gene (54). Pediatric T-ALL was engrafted in NOD/SCID 
mice to test responses to a novel monoclonal antibody against 
NOTCH1 (55). This antibody delayed engraftment in T-ALL 
samples with Notch1 mutations, even in samples derived from 
patients who were poorly responsive to previous therapy (55). 
Inducible overexpression of PRDM14, a pluripotency mainte-
nance gene for embryonic stem cells, in a Cre recombinase system 
in mice induces rapid onset highly penetrant T-ALL which also 
features high Notch1 activity with high expression of NOTCH1 
downstream targets. The T-ALL cells from this model are also 
sensitive to NOTCH1 inhibitor therapy (56). Interestingly, over-
expression of IL-15 in a transgenic mouse model produces large 
granular cell leukemia with a NK/T cell phenotype (57).
Chronic lymphocytic leukemia is the most common form of 
leukemia in the United States and is characterized by proliferation 
of CD5+ B cells in bone marrow, peripheral blood, and lymphoid 
tissues (58). A common genomic aberration in CLL leads to 
increased expression of anti-apoptotic protein BCL-2, which is 
negatively regulated by miR-15a and miR-16-1. The expression 
of these miRs is lost via deletion of a region on chromosome 13, 
13q14.3 (59, 60). Both of these miRs decrease Bcl-2 expression by 
posttranscriptional regulation resulting in induction of apoptosis 
(61). New Zealand Black mice develop a spontaneous clonal 
CD5+ B cell disease in old age, similar to a subtype of CLL in 
humans. This disease has been linked to a locus on murine chro-
mosome 14 with synteny to the human chromosomal locus lost in 
CLL. These mice also have reduced expression of miR-16-1 (62). 
Development of CLL in these mice is accelerated by induction of 
a heterozygous mutation in IRF4 (63).
The proto-oncogene T-cell leukemia 1 (TCL-1) is expressed 
in pre-B cells and early T-cell precursors. Overexpression of 
TCL-1 has been identified in multiple B-cell lymphomas and in 
the majority of CLL patients (64). The TCL-1 transgenic mouse 
mimics human CLL; however, disease development is delayed 
leading to practical issues with experimentation and therapeutic 
investigation (65). Serial transfer in TCL-1 transgenic mice 
allows rapid progression of the disease and has been useful for 
preclinical studies (64). One such study examined the efficacy of 
programmed cell death (PD-1) immune checkpoint inhibitors, 
an exciting therapeutic target for CLL (66). Additionally, crossing 
the TCL-1 mice with other GEMMs has aided in elucidating the 
role of other survival factors in CLL, such as ROR1 and BAFF 
(64). To model a common genetic alteration in the human dis-
ease, a transgenic mouse lacking the chromosomal region 13q14 
encoding for DLEU-2, miR-15, and miR-16 were developed (67). 
This mouse demonstrated a spectrum of lymphoproliferative 
disorders including a progressive CLL; however, the penetrance 
was poor (65).
Poor engraftment by CLL cells into mice has limited the 
utility of xenograft models for this disease. Engraftment models 
are improved in NOD/SCID mice, which have been used to 
characterize prognostic biomarkers (68). CLL cells depend on 
signaling from the microenvironment, and the use of NSG™ 
mice was then a great benefit to study microenvironment con-
tribution to disease development (69, 70). NSG™ mice were also 
used to demonstrate that the murine splenic microenvironment 
supported CLL cell proliferation to a similar degree as human 
lymph nodes with induction of BCR and NF-κB pathways. 
This model was also used to study the effects of ibrutinib on 
the microenvironment and tumor burden (71). Importantly, a 
CLL cell line was recently established from a patient and was 
maintained in coculture with autologous stromal cells. This line 
was readily transplantable into NSG™ mice that developed the 
multi-systemic disease (72).
Infection with human T-cell leukemia virus-1 (HTLV-1) 
causes adult T-cell leukemia (ATL) in a minority of infected 
people. Murine models have been used to study persistent viral 
infection and tumorigenesis induced by HTLV-1 protein expres-
sion through the use of transgenics, xenografts, and infection of 
humanized mice with the virus (73). Overexpression of onco-
genic Tax and HBZ viral proteins from HTLV-1 has elucidated 
mechanisms of leukemia development. Engraftment of ATL cell 
lines into SCID mice has been used to study tumor spread and 
metastasis, as well as for evaluation of novel therapeutics. Finally, 
humanizing mice with CD34+ cord stem cells and subsequently 
infecting them with HTLV-1 leads to leukemia development (73).
TABLe 4 | Murine models of lymphoma.
Disease Gene targets Model Translation Therapeutic use
B-cell lymphoma MYC Conditional transgenic using Ig heavy chain B-cell lymphoma, Burkitt’s lymphoma, 
diffuse large B-cell lymphoma




SYK MYC/BCR/sHEL transgenic B-cell lymphoma SYK inhibitors
Follicular lymphoma (FL) BCL-2 Transgenic linked to Vav regulatory sequence FL
EBV-induced disease Humanized mice infected with EBV B-cell lymphoproliferative disease, 
hemophagocytic lymphohistiocytosis
Peripheral T-cell lymphoma 
(PTCL)
ITK-SYK Inducible transgenic using CD4-Cre Disseminated PTCL SYK inhibitors
Anaplastic large cell lymphoma 
(ALCL)
NPM-ALK Inducible transgenic using CD4-Cre ALCL
Cutaneous T-cell lymphoma 
(CTCL)
IL-15 Transgenic CTCL HDAC inhibitors
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MURiNe MODeLS OF LYMPHOMA
B-cell lymphomas are the fourth most common hematologic 
malignancy in humans and the most common type of non-
Hodgkin’s lymphoma (74). The most common B-cell lymphomas 
are diffuse large B-cell lymphoma (DLBCL), follicular lympho-
mas (FLs), marginal zone lymphomas, and Burkitt’s lymphoma 
(BL) (74). Murine models of lymphoma have allowed the study of 
tumor biology, microenvironment, and mechanisms of response 
to therapy.
Translocation of the MYC oncogene to a site downstream of 
a B-cell specific enhancer or promoter region results in B-cell 
lymphoma. The transgenic murine model Eμ-MYC features 
MYC gene insertion into the IgH locus with a 100% incidence of 
B-cell lymphoma developing (74) (Table 4). This model features 
development of an immature form resembling BL and a more 
indolent mature form resembling DLBCL (75). Modification 
of similar models by an introduction of murine retroviruses 
expressing ras oncogene can be used to produce accelerated 
lymphomagenesis (76).
Follicular lymphoma is the second most common nodal lym-
phoma and progresses slowly with generally favorable response 
to therapy, but development of resistance is a common clinical 
problem (77). At (14:18) translocation in FL activates Bcl-2 
expression by linking it to the IgH locus. Use of the Vav gene 
regulatory sequences to drive Bcl-2 expression in mice results 
in the development of FL (78). This model was used to study 
the role of prolonged germinal center reactivity and V-gene 
hypermutation. Embryonic deletion of the activation-induced 
cytidine deaminase (AID) gene in mice prevented Bcl-6-driven 
FL, suggesting the important role of AID in the generation of 
additional genetic alterations in the pathogenesis of this disease 
(79). Spleen tyrosine kinase (SYK) was shown to be required for 
survival of non-Hodgkin lymphoma-like tumors in an Eμ-MYC/
BCR/sHEL-transgenic mouse. A specific inhibitor of Syk was 
used to cause tumor regression in vivo (80). One such study fur-
ther identified galectin-1, a carbohydrate-binding protein with 
diverse functions in immune response, as a key determinant in 
the development of resistance to antibody therapy (81).
Humanized mice infected with Epstein–Barr virus develop 
a B-cell lymphoproliferative disease and EBV-associated 
hemophagocytic lymphohistiocytosis. The use of these models 
has also elucidated the role in innate immune responses includ-
ing EBV-specific adaptive T-cell responses in these diseases (82). 
EBV-associated Hodgkin’s lymphomas developed in mice with 
activated T-cell environment, while non-Hodgkin’s lymphoma 
developed in T-cell depressed mice following infection with EBV 
(83). Further, EBV mutants with altered latency genes have been 
used to generate aggressive lymphoproliferative disease in mice, 
allowing the better understanding of the roles of these genes in 
disease pathogenesis (82).
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive 
form of non-Hodgkin lymphoma that responds poorly to stand-
ard chemotherapeutic treatment. A translocation was identified 
in a subset of PTCL patients featuring a fusion of ITK and SYK 
(84). Subsequently, a mouse model was developed using a loxP 
stop cassette to generate an inducible fusion protein crossed with 
CD4-Cre animals (85). The resulting transgenic mouse expressed 
the kinase fusion protein in T-cells and developed lymphoma 
mimicking disseminated PTCL. Additionally, this mouse 
demonstrated responsiveness to Syk inhibitors (85). A model of 
anaplastic large cell lymphoma, a PTCL of young adults, utilizes 
CD4/NPM-ALK transgenic mice with increased NOTCH1 
expression (86).
Cutaneous lymphomas are a heterogeneous group of non-
Hodgkin lymphoma that primarily affects the skin. While 
xenograft models are in use for therapeutic efficacy studies in 
cutaneous lymphoma, a model to study the development and 
progression of this rare disease has been lacking (87). Cutaneous 
T-cell lymphoma (CTCL) is the most typical of cutaneous lym-
phomas. A method of intrahepatic injection of CTCL-derived cell 
lines into NOD/SCID/IL2rγ mice resulted in successful engraft-
ment and had been used to evaluate cell line tumorigenicity as 
well as therapeutic responses in preclinical studies (88). Recently, 
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a transgenic mouse model with constitutive global overexpres-
sion of pro-inflammatory cytokine IL-15 was described, which 
develops a infiltration of the skin by mature T-cells characterized 
by the same immunophenotypic features as found in the human 
disease (89). Thus this model will be invaluable in investigations 
of lymphomagenesis in CTCL as well as clinical response to 
therapies with activity in a subset of human CTCL.
DiSCUSSiON
Development of translational murine models has been vital to 
the detailed mechanistic investigation into disease pathogenesis 
and identification of therapeutic targets. The mouse provides a 
valuable model system to study human disease in its genetic and 
physiologic similarity while being readily available and economi-
cally practical.
One needs to look no further than the failure rate of newly 
developed therapeutics to understand the importance of appro-
priate interpretation of mouse data. While murine models are 
frequently used for preclinical investigations of novel drug tar-
gets, success in these studies is often poorly predictive of success 
in the clinic. Indeed, the average rate of successful advancement 
from animal models to clinical trials for cancer drugs is less 
than 8% (90). Of compounds that are successful in preclinical 
modeling, 85% of early human trials fail (90). This attrition rate 
can be improved by careful consideration, selection, and design 
of murine models (91, 92). Unfortunately, there are currently 
no best-practice standards for animal testing, and study design 
practices are variable.
In this review, the following considerations for a researcher 
designing and utilizing a murine model have been emphasized: 
is the mouse the most appropriate in vivo model? What are the 
background lesions or strain characteristics that could confound 
my study? Am I expressing my gene of interest in the right cell 
type context and at the right time in disease development? Is the 
model disease similar genetically, morphologically, and pheno-
typically to the human condition? Ultimately, the usefulness of 
the model must be tempered by its shortcomings, and therefore, 
the use of murine models must be approached with a thorough 
understanding of both its utility and limitations.
One final question, Is there a better way? Phase “0” studies 
utilize miniscule doses of novel drugs in human subjects to col-
lect data on pharmacodynamics and target specificity (90, 93). 
An exciting alternative to animal studies in preclinical research 
is the “organ on a chip” methodology which recapitulates the 
organ structure, microenvironment, and physiological function 
by implanting the organ onto silicon chips (90, 94). This technol-
ogy may allow faster and less expensive drug development with 
the ability to successfully and faithfully mimic disease states on a 
chip. Thus far, this technology has not been used to address the 
pathology of liquid tumors. However, the field is quickly advanc-
ing and, may shortly, allow in vitro examination of hematopoietic 
systems and hematopoietic neoplasia.
Although the mouse’s reign as king in biomedical research 
will likely continue for many years, appropriate model design, 
thorough characterization and excellent new technologies will 
allow researchers to strive further to replace, reduce, and refine 
their use.
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